Utilizing data analytics to adhere to DOJ guidance on corporate compliance programs

Implementing and utilizing data analytics within the compliance and monitoring function of life sciences companies can seem like a daunting task. Additionally, with the U.S. Department of Justice’s (DOJ) revised guidance on corporate compliance programs, the importance of utilizing analytics is changing the industry. Now that the DOJ is taking a more proactive approach of identifying companies that have gaps in their compliance programs, through the use of data analytics themselves, establishing a culture of compliance that incorporates data-driven insights has never been greater. Incorporating data analytics into your compliance program has instantly changed from a “nice to have” to a “must have” element of your program.  

Listen to Baker Tilly’s informative, on-demand webinar about the DOJ’s guidance on corporate compliance programs and the importance of data analytics within your life science company’s compliance function. In addition to providing an overview of the recent guidance, the presentation discusses best practices when implementing and utilizing analytics and dashboards. Finally, the discussion wraps up with a case study/use case of a medical device company that is adhering to the recent DOJ guidance. 

For more information on this topic, or to learn how Baker Tilly’s Value Architects™ can help,